Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PLX
Previous SymbolNYSEMKT:PLX
CUSIPN/A
Phone+972-4-9028100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees190
Outstanding Shares148,380,000
Market Cap$0.00
OptionableOptionable
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.06. The firm earned $0.66 million during the quarter, compared to analysts' expectations of $8 million. During the same quarter in the prior year, the business earned ($0.09) earnings per share. View Protalix Biotherapeutics' Earnings History.
When is Protalix Biotherapeutics' next earnings date?
What price target have analysts set for PLX?
1 analysts have issued 1 year price objectives for Protalix Biotherapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Protalix Biotherapeutics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,011.1% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.
What is the consensus analysts' recommendation for Protalix Biotherapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.
What are Wall Street analysts saying about Protalix Biotherapeutics stock?
Here are some recent quotes from research analysts about Protalix Biotherapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our model yields an rNPV of $280M for PRX-102 using a 15% discount rate and 75% probability of approval, accounting for the receipt of royalties on PRX-102 sales globally. We also ascribe an rNPV of $230M to alidornase alfa, a $100M rNPV for $50M rNPV for OPRX-106, translating into a price per share of $4.00. This assumes 149M shares outstanding as of end-2019." (12/13/2018)
- 2. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (11/14/2018)
Has Protalix Biotherapeutics been receiving favorable news coverage?
Media coverage about PLX stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Protalix Biotherapeutics earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Are investors shorting Protalix Biotherapeutics?
Protalix Biotherapeutics saw a drop in short interest during the month of November. As of November 30th, there was short interest totalling 3,008,558 shares, a drop of 0.9% from the November 15th total of 3,034,465 shares. Based on an average daily volume of 130,814 shares, the days-to-cover ratio is currently 23.0 days. Approximately 2.2% of the company's shares are sold short. View Protalix Biotherapeutics' Current Options Chain.
Who are some of Protalix Biotherapeutics' key competitors?
Some companies that are related to Protalix Biotherapeutics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Protalix Biotherapeutics' key executives?
Protalix Biotherapeutics' management team includes the folowing people:
- Mr. Moshe Manor, CEO, Pres & Director (Age 62)
- Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 64)
- Mr. Yossi Maimon CPA, MBA, CFO, VP, Treasurer & Sec. (Age 47)
- Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 58)
- Mr. Yaron Naos, Sr. VP of Operations (Age 55)
Who are Protalix Biotherapeutics' major shareholders?
Protalix Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.20%), Fosun International Ltd (1.77%) and Opaleye Management Inc. (1.68%). Company insiders that own Protalix Biotherapeutics stock include Madalena Energy Inc, Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Institutional Ownership Trends for Protalix Biotherapeutics.
Which major investors are selling Protalix Biotherapeutics stock?
Which major investors are buying Protalix Biotherapeutics stock?
PLX stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd and Renaissance Technologies LLC. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Moshe Manor, Randall Peel Boyd, Steve Dabner and Terence Stanley Meek. View Insider Buying and Selling for Protalix Biotherapeutics.
How do I buy shares of Protalix Biotherapeutics?
Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
One share of PLX stock can currently be purchased for approximately $0.36.
What is Protalix Biotherapeutics' official website?
How can I contact Protalix Biotherapeutics?
Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.
MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
